Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Bristol Myers Squibb and Exelixis, Inc. have released the four-year follow-up findings from the CheckMate -9ER trial, which investigated the efficacy of Opdivo® (nivolumab) combined with CABOMETYX® (cabozantinib) versus sunitinib in patients with advanced or metastatic renal cell carcinoma (RCC) who had not been previously treated. The results consistently demonstrated improved progression-free survival (PFS) and objective response rates (ORR) among patients treated with Opdivo in conjunc...